Compare Affirm Holdings Inc (AFRM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Affirm Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Affirm Holdings Inc trades at $80.3 (market cap $28.00B), while Recursion Pharmaceuticals Inc trades at $3.69 (market cap $2.04B). The key difference: Affirm Holdings Inc is far larger — about 13.7× Recursion Pharmaceuticals Inc's market cap, and Affirm Holdings Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AFRM | RXRX | |
|---|---|---|
Market Cap | $28.00B | $2.04B |
Sector | Financials | Health |
52-Week High | $92.18 | $6.79 |
52-Week Low | $42.53 | $2.84 |
Enterprise Value | $34.61B | $1.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $83.62, down 1.14% on the day, with a bullish technical outlook supported by moving averages and a golden cross pattern. The company reported strong revenue growth, reaching $3.22 billion in 2025, and has consistently beaten earnings expectations in recent quarters. Recent partnerships with Bed Bath & Beyond and Backcountry expand its merchant network, driving transaction volume growth.
The outlook remains positive with analyst consensus favoring a buy rating and a $89 price target, though high valuation multiples and overbought RSI levels pose near-term risks. Earnings growth and BNPL market expansion are key catalysts, while credit losses and competition represent ongoing challenges for shareholders.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
